Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Across all cancers: a drug is placed once, at the highest stage it reaches anywhere. Representative drugs are those with the most active trials at that stage.
86 drugs · 711 active trials
22 drugs · 920 active trials
348 drugs · 19,214 active trials
Outside the funnel: Withdrawn 25. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 6 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Lorlatinib | Approved | Phase 4 | 21 | 8 | 3 | 40 | 5 | CA, EU, US | Nov 2, 2018 | Jan 8, 2014 |
| Lutetium (177lu) Oxodotreotide | Approved | Phase 4 | 21 | 13 | 3 | 34 | 2 | CA, EU | Sep 26, 2017 | Mar 1, 2007 |
| Bleomycin | Approved | Phase 4 | 20 | 10 | 54 | 122 | 6 | CA, US | Mar 12, 1998 | 1989-04 |
| Axicabtagene Ciloleucel | Approved | Phase 4 | 20 | 12 | 5 | 36 | 2 | CA, EU | Aug 23, 2018 | Apr 21, 2015 |
| Revumenib | Approved | Phase 3 | 20 | 13 | 3 | 25 | 2 | US | Nov 15, 2024 | 2016-11 |
| Afatinib | Approved | Phase 4 | 19 | 10 | 17 | 146 | 20 | CA, EU, US | Jul 12, 2013 | 2003-11 |
| Cabazitaxel | Approved | Phase 4 | 19 | 9 | 17 | 102 | 13 | CA, EU, US | Jun 17, 2010 | 1999-10 |
| Neratinib | Approved | Phase 3 | 19 | 14 | 3 | 66 | 9 | CA, EU, US | Jul 17, 2017 | 2003-11 |
| Elotuzumab | Approved | Phase 3 | 19 | 6 | 14 | 60 | 11 | CA, EU, US | Nov 30, 2015 | 2006-12 |
| Tazemetostat | Approved | Phase 3 | 19 | 4 | 1 | 49 | 4 | US | Jan 23, 2020 | Jun 13, 2013 |
| Aumolertinib | Approved | Phase 3 | 19 | 10 | 15 | 44 | 1 | EU | Feb 12, 2026 | May 8, 2017 |
| Adagrasib | Approved | Phase 3 | 19 | 9 | 5 | 33 | 5 | EU, US | Dec 12, 2022 | Jan 15, 2019 |
| Zanidatamab | Approved | Phase 3 | 19 | 13 | 5 | 27 | 7 | CA, EU, US | Nov 20, 2024 | Mar 1, 2010 |
| Mitoxantrone | Approved | Phase 4 | 18 | 8 | 51 | 216 | 6 | CA, US | Apr 11, 2006 | 1991-02 |
| Vemurafenib | Approved | Phase 4 | 18 | 7 | 11 | 116 | 9 | CA, EU, US | Aug 17, 2011 | 2006-11 |
| Ixazomib | Approved | Phase 4 | 18 | 4 | 7 | 112 | 6 | CA, EU, US | Nov 20, 2015 | Mar 2, 2009 |
| Thioguanine | Approved | Phase 4 | 18 | 10 | 44 | 84 | 2 | CA, US | Jan 18, 1966 | 1993-01 |
| Calaspargase Pegol | Approved | Phase 3 | 18 | 9 | 7 | 22 | 2 | CA, US | Dec 20, 2018 | Jul 21, 2008 |
| Linvoseltamab | Approved | Phase 4 | 18 | 15 | 6 | 19 | 1 | EU | Apr 23, 2025 | Jan 23, 2019 |
| Pazopanib | Approved | Phase 4 | 17 | 9 | 16 | 203 | 12 | CA, EU, US | Oct 19, 2009 | 2002-12 |
| Lomustine | Approved | Phase 3 | 17 | 7 | 28 | 86 | 5 | CA, US | Aug 4, 1976 | 1994-07 |
| Gemtuzumab Ozogamicin | Approved | Phase 4 | 17 | 13 | 17 | 85 | 7 | CA, EU, US | Sep 1, 2017 | 1997-02 |
| Ponatinib | Approved | Phase 3 | 17 | 9 | 5 | 55 | 10 | CA, EU, US | Dec 14, 2012 | 2008-06 |
| Enasidenib | Approved | Phase 3 | 17 | 10 | 2 | 33 | 4 | CA, US | Aug 1, 2017 | Aug 27, 2013 |
| Relugolix | Approved | Phase 3 | 17 | 11 | 13 | 33 | 4 | CA, EU, US | Dec 18, 2020 | 2011-10 |
| Lifileucel | Approved | Phase 3 | 17 | 9 | 1 | 29 | 1 | CA | — | May 15, 2015 |
| Entrectinib | Approved | Phase 3 | 17 | 8 | 6 | 28 | 8 | CA, EU, US | Aug 15, 2019 | Jul 28, 2014 |
| Nilotinib | Approved | Phase 4 | 16 | 7 | 27 | 123 | 31 | CA, EU, US | Oct 29, 2007 | Jul 13, 2001 |
| Pacritinib | Approved | Phase 3 | 16 | 12 | 2 | 36 | 1 | US | Feb 28, 2022 | 2008-07 |
| Asciminib | Approved | Phase 4 | 16 | 9 | 6 | 26 | 10 | CA, EU, US | Oct 29, 2021 | Apr 24, 2014 |
| Selpercatinib | Approved | Phase 4 | 16 | 2 | 3 | 18 | 26 | CA, EU, US | May 8, 2020 | 2016-08 |
| Celecoxib | Approved | Phase 4 | 15 | 11 | 27 | 192 | 10 | EU, US | Dec 31, 1998 | 1998-03 |
| Hydroxychloroquine | Approved | Phase 4 | 15 | 6 | 1 | 85 | 2 | US | Apr 18, 1955 | 2007-07 |
| Lazertinib | Approved | Phase 3 | 15 | 6 | 4 | 27 | 5 | CA, EU, US | Aug 19, 2024 | May 24, 2016 |
| Ziftomenib | Approved | Phase 3 | 15 | 12 | 1 | 15 | 1 | US | Nov 13, 2025 | Sep 12, 2019 |
| Carmustine | Approved | Phase 3 | 14 | 9 | 36 | 191 | 8 | CA, EU, US | Dec 31, 1975 | 1988-04 |
| Vismodegib | Approved | Phase 4 | 14 | 9 | 0 | 71 | 4 | CA, EU, US | Jan 30, 2012 | 2007-04 |
| Dactinomycin | Approved | Phase 4 | 14 | 8 | 27 | 50 | 6 | CA, US | Dec 31, 1963 | 1991-10 |
| Levoleucovorin | Approved | Phase 3 | 14 | 7 | 12 | 39 | 1 | US | Oct 19, 2018 | 1997-10 |
| Nirogacestat | Approved | Phase 4 | 14 | 5 | 1 | 25 | 2 | EU, US | Nov 27, 2023 | Jun 25, 2009 |
| Ensartinib | Approved | Phase 4 | 14 | 3 | 2 | 22 | 1 | US | Dec 18, 2024 | Mar 6, 2017 |
| Arsenic Trioxide | Approved | Phase 4 | 13 | 6 | 11 | 112 | 18 | CA, EU, US | Sep 25, 2000 | 1997-11 |
| Triptorelin | Approved | Phase 4 | 13 | 9 | 22 | 58 | 8 | CA, US | Jun 15, 2000 | 1997-04 |
| Pemigatinib | Approved | Phase 3 | 13 | 11 | 1 | 43 | 7 | CA, EU, US | Apr 17, 2020 | Feb 27, 2015 |
| Mirvetuximab Soravtansine | Approved | Phase 3 | 13 | 7 | 5 | 25 | 4 | CA, EU, US | Nov 14, 2022 | Jun 28, 2012 |
| Erdafitinib | Approved | Phase 3 | 13 | 1 | 1 | 24 | 8 | CA, EU, US | Apr 12, 2019 | Apr 22, 2015 |
| Loncastuximab Tesirine | Approved | Phase 3 | 13 | 8 | 2 | 24 | 3 | CA, EU, US | Apr 23, 2021 | 2016-03 |
| Camizestrant | Approved | Phase 3 | 13 | 6 | 6 | 22 | 3 | CA, EU, US | Jul 20, 2026 | Oct 11, 2018 |
| Zolbetuximab | Approved | Phase 4 | 13 | 5 | 4 | 19 | 5 | CA, EU, US | Sep 19, 2024 | May 31, 2009 |
| Larotrectinib | Approved | Phase 4 | 13 | 5 | 0 | 15 | 10 | CA, EU, US | Nov 26, 2018 | May 4, 2014 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.